Malifa Capsule 30 mg

Malifa Capsule 30 mg Uses, Dosage, Side Effects, Food Interaction and all others data.

Malifa Capsule 30 mg is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate. Malifa Capsule 30 mg has been described in literature since at least the late 1980s as a potential treatment for iron deficiency.

Malifa Capsule 30 mg was granted FDA Approval on 25 July 2019.

Malifa Capsule 30 mg is used to provide supplemental iron to patients with an iron deficiency. It has a wide therapeutic index as patients generally take 30mg twice daily, while concentrations of 20mg/kg may produce toxicity. Patients should be counselled regarding the risk of inflammatory bowel disease flares, iron overload, and accidental ingestion in children.

Malifa Capsule 30 mg
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Malifa Capsule 30 mg
Generic	Ferric maltol
Ferric maltol Other Names	Ferric maltol, Iron (III) maltol
Weight	30 mg
Type	Capsule
Formula	C₁₈H₁₅FeO₉
Weight	Average: 431.154 Monoisotopic: 431.006543
Protein binding	Data regarding the protein binding of ferric maltol is not readily available.
Groups	Approved
Therapeutic Class
Manufacturer	Navana Pharmaceuticals Ltd.
Available Country	Bangladesh
Last Updated:	October 19, 2023 at 6:27 am

Uses

Malifa Capsule 30 mg is a complexed iron supplement used to treat iron deficiency in adults.

Malifa Capsule 30 mg is indicated to treat iron deficiency in adults.

Malifa Capsule 30 mg is also used to associated treatment for these conditions: Iron Deficiency (ID)

How Malifa Capsule 30 mg works

Malifa Capsule 30 mg dissociates as the iron atom is donated to unknown iron uptake mechanisms, possibly beta 3 integrin or divalent metal transporter 1, in the ileum and duodenum. Once the iron is in circulation, it then associates with transferrin and ferritin.

Toxicity

Data regarding overdoses of ferric maltol are not readily available, however toxicity is expected with acute ingestion of 20mg/kg and 200-250mg/kg is potentially fatal. Patients experiencing an overdose may present with nausea, vomiting, abdominal pain, diarrhea, hypoperfusion, metabolic acidosis, and systemic toxicity. Overdoses should be treated with symptomatic and supportive measures which may include the use of desferroxamine. Hemodialysis will not remove iron but will remove the iron-desferroxamine complex.

Food Interaction

Take on an empty stomach.

Volume of Distribution

Data regarding the volume of distribution of ferric maltol is not readily available.

Elimination Route

Malifa Capsule 30 mg dissociates in the gastrointestinal tract, leading to a T_max of 1.5-3.0 hours for iron concentrations. Mean serum iron increases by 14±6µmol/L in iron deficient patients following a single dose. a 60mg dose is approximately 14% bioavailable. 60 minutes after injection of radiolabelled ferric maltol, 11+2% of the dose is present in the bone marrow, 18±1% is present in the liver, and 2.6±1% is in the urine. Maltol has an AUC of 0.022-0.205h*µg/mL and maltol glucuronide has an AUC of 9.83-30.9h*µg/mL.

Half Life

Maltol has a half life of 0.7h.

Clearance

Data regarding the clearance of ferric maltol is not readily available.

Elimination Route

39.8-60% of an oral dose of ferric maltol is excreted in the urine as a glucuronide conjugate. Iron and ferric maltol are not excreted in the urine and unabsorbed ferric maltol is eliminated in the feces.